Pune, Oct. 27, 2022 (GLOBE NEWSWIRE) — According to the latest report published by Growth Plus Reports, the global Therapeutics for generalized anxiety disorder is expected o’clock $12193 million by 2030 and grow at a CAGR of 3.6% during the forecast period. This exclusive information is published by Growth Plus Reports in its report titled Generalized Anxiety Disorder Therapeutics Market – Global Outlook and Forecast 2022-2030.
growth accelerator
The socioeconomic impact of mental health problems will continue to increase through associated job losses and impacts on lifestyle and social engagement. Pharmaceutical companies are stepping up efforts to accelerate the commercialization of treatments for anxiety and depression. This has prompted various governments to launch initiatives aimed at reducing the burden of mental illness and anxiety disorders.
The global Generalized Anxiety Disorder Therapeutics market has been analyzed from three perspectives: drug class, distribution channel, and region
Get a sample copy of the research report: https://growthplusreports.com/inquiry/request-sample/generalized-anxiety-disorder-therapeutics-market/7905
Excerpts from “Segmentation by Drug Class”
Based on Drug Class, the Global Generalized Anxiety Disorder Therapeutics Market is segmented into:
- antidepressants
- azapirones
- benzodiazepines
- Other
The antidepressants are further divided into selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), and others. The antidepressant segment dominated the generalized anxiety disorder treatment market due to the drug’s higher potency in reducing the symptoms of anxiety and other related mental illnesses. Many antidepressants, including selective serotonin reuptake inhibitors, are considered first-line treatments for generalized anxiety disorder because they have been shown to relieve symptoms. An increase in…
